The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Johan Lochen, Erik Penser Bank. Phone: +46 8 463 80 00. Erik Penser Bank equity research

Felicia Rittemar, Vator Securities, Phone: +46 8 5333 2737. Vator Securities equity research

Annual Report

  December 17, 2019

Company Presentation

  Annual report 19/20, November 5, 2020

Dear Shareholders and readers

This year has been transformative for Diamyd Medical. In December 2019, and later published in August 2020 in Diabetologia, we could show with data from more than 500 patients from three trials, that the individual’s genes, more specifically the HLA genes of the individual, influences the treatment effect of the diabetes vaccine Diamyd®. To confirm this finding in a prospective trial, the same analysis was specified as a part of the main analysis in the statistical analysis protocol and included...

Our data support the therapeutic targeting of individuals that carry the specific HLA genes that associate with the therapeutic antigen, in this case HLA DR3-DQ2 and GAD. This paves the way for a precision medicine approach in type 1 diabetes for the diabetes vaccine Diamyd®.
Ulf Hannelius, President and CEO

Calendar

  
January 20, 2021
Quarterly Report I
Quarterly Report 1 2020/2021
March 31, 2021
Quarterly Report II
Quarterly Report 2 2020/2021
June 23, 2021
Quarterly Report III
Quarterly Report 3 2020/2021
October 6, 2021
Year-End Report
Year-End Report 2020/2021
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of September 30, 2020

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 9 050 544 13.08 9.82
Essen-Möller, Anders 2 556 223 6 333 040 12.85 34.60
Lindkvist, Bertil 6 500 000 9.40 7.05
Nordnet Pension 2 285 303 3.30 2.48
Swedbank Försäkring 844 899 1.22 0.92
Konstruktions o Försäljningsaktiebolag 750 745 1.09 0.81
Arandi Development AB 514 000 0.74 0.56
Relbo AB 475 550 0.69 0.52
Lindberg, Mikael 460 021 0.67 0.50
Schelé, Sven 460 000 0.67 0.50
Remaining shareholders 38 939 471 56.30 42.24
Total 2 556 223 66 613 573 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS